Roche receives FDA approval for first companion diagnostic to identify dMMR solid tumour patients eligible for anti-PD-1 immunotherapy
- Cancer is the second leading cause of death worldwide, with nearly 10 million deaths annually.1, 2 In the U.S., approximately 1.9 million new cancer cases are expected to be diagnosed in 2021.1
- Based on cancer biomarkers, the first-of-its-kind VENTANA MMR RxDx Panel helps determine which solid tumour patients may benefit from GSK immunotherapy.
- Roche/GSK collaboration represents an important step towards a personalised healthcare strategy for certain solid tumour patients.
Basel, 18 August 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced U.S. Food and Drug Administration (FDA) approval of the VENTANA MMR RxDx Panel, advancing the company's commitment to personalised healthcare through tests that determine which patients are most likely to benefit from specific and targeted therapies. The VENTANA MMR RxDx Panel is the first companion diagnostic test to aid in identifying patients whose solid tumours are deficient in DNA mismatch repair (MMR), who may be eligible for JEMPERLI (dostarlimab-gxly) monotherapy, an anti-PD-1 immunotherapy from GSK. The test evaluates a panel of MMR proteins in tumours to provide important treatment information to clinicians.
MMR is a naturally occurring mechanism that scans our DNA, correcting errors that cause disease. When MMR is deficient (dMMR), cells mutate, which can lead to cancer. While MMR deficiency is most common in endometrial cancer, other high prevalence dMMR tumour types include gastric, colorectal, small intestine, cervical and neuroendocrine cancers. In the U.S., prevalence of dMMR across patients with solid tumours has been estimated at 14 percent.3 PD-1 inhibitors can be effective treatment in cancers with MMR deficiency.
"As the first companion diagnostic of its kind, this test can help qualify patients with solid tumours that are deficient in MMR who have progressed in their disease and who have no other suitable treatment options,” said Thomas Schinecker, CEO Roche Diagnostics. “Based on the results of our MMR biomarker test, these patients may be eligible to receive GSK’s JEMPERLI. We are pleased that our innovative companion diagnostic label continues to grow to serve more patients.”
FDA approval of the VENTANA MMR RxDx Panel provides clinicians with access to a fully automated panel of MMR biomarkers tested by immunohistochemistry (IHC), enabling impactful treatment decisions for patients. JEMPERLI was approved by the FDA on 17 August 2021 for the treatment of adult patients with dMMR recurrent or advanced solid tumours, as determined by an FDA-approved test, that have progressed on or following prior treatment and who have no satisfactory alternative treatment options. This indication received accelerated approval based on tumour response rate and durability of response. Continued approval for this indication may depend on verification and description of clinical benefit in a confirmatory trial(s).
The VENTANA MMR RxDx Panel and JEMPERLI were earlier approved by the FDA for use in endometrial cancer in April 2021.
Read more about Roche innovation in MMR biomarker testing.
About the VENTANA MMR RxDx Panel
The VENTANA MMR RxDx Panel is a label expansion of Roche’s current on-market VENTANA MMR IHC Panel. The VENTANA MMR RxDx Panel is intended for the assessment of expression of MMR proteins in formalin-fixed, paraffin-embedded (FFPE) tumour tissue stained with OptiView DAB IHC Detection Kit and ancillary reagents in the panel for VENTANA anti-MLH1 (M1), VENTANA anti-MSH2 (G219-1129) and VENTANA anti-MSH6 (SP93) and OptiView DAB IHC Detection Kit with the OptiView Amplification Kit and ancillary reagents for VENTANA anti-PMS2 (A16-4) on a BenchMark ULTRA instrument. DNA mismatch repair (MMR) proteins have been clinically proven to be predictive biomarkers for PD-1 targeted therapy; specifically, a loss of expression of one or more MMR proteins might predict an increased likelihood of response to such therapy.4,5,6 PD-1 inhibitors can be effective in cancers with MMR deficiency.4,6 MMR is a conserved molecular mechanism that functions to correct the improper base substitutions that spontaneously occur during DNA replication. Defects in the MMR machinery have been attributed to mutations in the MMR proteins.
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics, as well as growing capabilities in the area of data-driven medical insights help Roche deliver truly personalised healthcare. Roche is working with partners across the healthcare sector to provide the best care for each person.
Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. In recent years, Roche has invested in genomic profiling and real-world data partnerships and has become an industry-leading partner for medical insights.
Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. More than thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Moreover, for the twelfth consecutive year, Roche has been recognised as one of the most sustainable companies in the Pharmaceuticals Industry by the Dow Jones Sustainability Indices (DJSI).
The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2020 employed more than 100,000 people worldwide. In 2020, Roche invested CHF 12.2 billion in R&D and posted sales of CHF 58.3 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.
All trademarks used or mentioned in this release are protected by law.
 Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020:70(1):7-30.
 Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019:69(1):7-34
 Lorenzi M, Amonkar M, Zhang J, et al. Epidemiology of microsatellite instability high (MSI-H) and deficient mismatch repair (dMMR) in solid tumors: a structured literature review. J Oncol. 2020. doi.org/10.1155/2020/1807929
 Lee YC, S Lheureux, and AM Oza. Treatment strategies for endometrial cancer: current practice and perspective. Curr Opin Obstet Gynecol. 2017:29:47-58.
 GSK website, https://www.gsk.com/en-gb/media/press-releases/data-from-garnet-study-indicates-robust-activity-of-dostarlimab-in-patients-with-advanced-or-recurrent-endometrial-cancer/
 Kato M, Takano M, Miyamoto M, et al. DNA mismatch repair-related protein loss as a prognostic factor in endometrial cancers. J Gynecol Oncol. 2015:26(1):40-45.
Roche Group Media Relations
Phone: +41 61 688 8888 / e-mail: email@example.com
|Dr. Nicolas Dunant|
Phone: +41 61 687 05 17
Phone: +41 61 688 44 86
|Dr. Barbara von Schnurbein|
Phone: +41 61 687 89 67
Phone: +41 61 682 28 31
Phone: +41 79 327 54 74
Phone: +41 61 687 43 05
|Roche Investor Relations|
|Dr. Karl Mahler|
Phone: +41 61 68-78503
|Jon Kaspar Bayard|
Phone: +41 61 68-83894
|Dr. Sabine Borngräber|
Phone: +41 61 68-88027
|Dr. Bruno Eschli|
Phone: +41 61 68-75284
|Dr. Birgit Masjost|
Phone: +41 61 68-84814
|Dr. Gerard Tobin|
Phone: +41 61 68-72942
|Investor Relations North America|
Phone: +1 650 225 3217
AttachmentTo view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
Jotul Holdings SA to redeem its outstanding up to NOK 400,000,000 senior secured floating rate bonds with ISIN NO001081574928.9.2021 22:25:00 CEST | Press release
Jotul Holdings SA hereby announces that its up to NOK 400,000,000 senior secured floating rate bonds with ISIN NO0010815749 (the "Bonds") will be redeemed in advance in accordance with Clause 9.3 (Voluntary total redemption (call option)) of the terms and conditions of the Bonds. The redemption date will be 25 October 2021. The redemption amount for each Bond shall be 100.00 per cent. of the nominal amount, plus accrued but unpaid interest up to, but excluding, the applicable redemption date. The redemption amount will be paid to the bondholders holding Bonds on the applicable record date (being 21 October 2021). Jotul Holdings SA's obligation to redeem the Bonds on the redemption date is conditional upon Jøtul AS, prior to the applicable record date, issuing senior secured floating rate bonds (the "New Bonds") and Jøtul AS fulfilling the conditions precedent for disbursement of the net proceeds from the issue of the New Bonds, which are, among other things, to be applied towards (i) f
Inventiva announces participation at several investor conferences in October 202128.9.2021 22:00:00 CEST | Press release
Daix (France), Long Island City (New York, United States), September 28, 2021 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS) and other diseases with significant unmet medical need, today announced that the Company’s leadership will participate in three upcoming investor conferences in October 2021. The event details are as follows: Conference n°1: HealthTech Innovation Days 2021 Event type: One-on-one investor meetings Date: Monday-Tuesday, October 4-5, 2021 Time: 3:00 am – 12:00 pm (ET) / 9:00 am – 6:00 pm (CET) Format: Hybrid event Conference n°2: Portzamparc Health Biotech Seminar Event type: One-on-one investor meetings Date: Wednesday, October 6, 2021 Time: 3:00 am – 12:15 pm (ET) / 9:00 am – 6:15 pm (CET) Format: Hybrid event Conference n°3: H.C. Wainwright 5th Annual NASH Investor Conference E
Avance Gas Holding Ltd enter into three Time Charter Agreements28.9.2021 18:30:00 CEST | Press release
Bermuda, 28 September 2021 – Avance Gas Holding Ltd (“AGAS” or the “Company”) is pleased to announce that we have entered into three Time Charter Agreements for a period of 2 years at an average hire level of approximately $30,000 per day net to owners for the 2008-built VLGC Iris Glory and Venus Glory and the 2009-built VLGC Promise. The vessels are delivered in September and October 2021. For further queries, please contact: Kristian Sørensen, CEO Tel: +47 22 00 48 10 Email: firstname.lastname@example.org Randi Navdal Bekkelund, CFO Tel: +47 22 00 48 29 Email: email@example.com About Avance Gas: Avance Gas operates in the global market for transportation of liquefied petroleum gas (LPG). The Company is one of the world's leading owners and operators of very large gas carrier (VLGC) and operates a fleet of thirteen modern ships and six Dual Fuel LPG newbuildings due for delivery in Q4 2021, Q1 2022, Q4 2022 and Q1-Q4 2023. For more information about Avance Gas, please visit
Phoenix Software Delivers First Enhancement to JES3 Technology in Six Years with JES3plus® V1R128.9.2021 18:00:00 CEST | Press release
Phoenix Software released updates to its product line in September 2021 EL SEGUNDO, Calif., Sept. 28, 2021 (GLOBE NEWSWIRE) -- Phoenix Software International, Inc., today announced the general availability of JES3plus V1R1, a derivative work based on IBM’s z/OS® JES3. This release integrates SPOOL I/O performance enhancements made available to JES3plus customers through continuous delivery earlier this year. This is the first release of the JES3 technology to contain enhancements since early 2015 and coincides with z/OS 2.5, the last release of z/OS to include JES3. Organizations looking to remain on this technology who migrate to JES3plus can now reap the benefits of an enhanced product with a roadmap for future development. JES3plus V1R1 JES3plus V1R1 supports two newer channel programming techniques to improve performance: ACKD – channel programs with a shortened prefix that can process an entire track instead of one record at a time. This enhancement leverages MIDAW support.zHPF –
Roman Sonderegger named new CEO of Schweiter Technologies28.9.2021 18:00:00 CEST | Press release
Ad hoc announcement pursuant to Art. 53 LR Steinhausen, 28 September 2021 – The Board of Directors of Schweiter Technologies AG has appointed Roman Sonderegger as the new CEO of the Schweiter Technologies Group. The 45-year-old Swiss citizen is currently Head of Business Unit Wheat & Rye at the Bühler Group and will take up his new position on 1 May 2022, succeeding Heinz Baumgartner, who will continue to lead the Group until his departure as previously announced. Heinz Baumgartner has been with Schweiter Technologies since 1996 and CEO of the Group since 2008. Under his leadership, the company has adopted a new strategic focus on the composites business and continued to develop through organic growth and acquisitions. In connection with the planned change in senior management, he will leave his role as CEO, at his own request, in 2022 once the familiarization period of his successor has been completed, but will remain a member of the Board of Directors. The Board of Directors would li
LIDDS patent covering the NanoZolid® production process granted in Russia and Australia28.9.2021 16:00:00 CEST | Press release
UPPSALA, SWEDEN – LIDDS AB (publ) announces today that its most recent patent family on the NanoZolid® production process, and hence achieved pharmaceutical products, has been granted in Russia and Australia. The patent provides protection until 2037 in these markets. “This patent is central to LIDDS and significantly broadens our patent protection. The product aspect of the patent improves the ability to detect infringement and it further strengthens our already strong IP portfolio. The decision from the patent authorities in Russia and Australia gives us important protection for our production process, and hence the pharmaceutical products that we derive from this process,” said Nina Herne, CEO of LIDDS. Recently, LIDDS has received patent approvals in Russia (patent no. 275334) and Australia (patent no. 201734489). The invention covering process and products based on the NanoZolid® technology provides protection until 2037. Furthermore, the patent protects all pharmaceutical product
CorelDRAW Introduces Valuable Subscriber Updates & New CorelDRAW Technical Suite, Completing its 2021 Professional Graphics Lineup28.9.2021 15:32:18 CEST | Press release
CorelDRAW Graphics Suite subscribers get integrated access to Google Fonts library, dynamic asset management and collaboration workflow enhancements, enabling designers to maximize their creativity while remaining connected. Latest version of CorelDRAW Technical Suite simplifies technical graphics workflows with advanced tools that accelerate productivity and deliver precise results. OTTAWA, Sept. 28, 2021 (GLOBE NEWSWIRE) -- Corel extends its CorelDRAW® 2021 professional product family with new subscriber-exclusive updates for CorelDRAW Graphics Suite 2021 and unveils CorelDRAW Technical Suite 2021, the newest edition of its comprehensive software collection for high-impact technical design and documentation. Whether they choose CorelDRAW® Graphics Suite or CorelDRAW® Technical Suite, subscribers can now enjoy a more flexible way to stay up to date with productivity-boosting dynamic asset management and collaboration workflow enhancements, additional fonts, creative templates and more